Differential T cell immune responses to deamidated adeno-associated virus vector
Despite the high safety profile demonstrated in clinical trials, the immunogenicity of adeno-associated virus (AAV)-mediated gene therapy remains a major hurdle.Specifically, T-cell-mediated immune responses to AAV vectors are related to loss of efficacy and potential liver toxicities.As post-translational modifications in T cell epitopes have the